CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab Mar 05, 2026 8:30am EST Press Release
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference Feb 20, 2026 8:30am EST Press Release
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer Jan 27, 2026 8:30am EST Press Release
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium Dec 08, 2025 8:30am EST Press Release
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium Nov 24, 2025 8:30am EST Press Release
CytoDyn to Present at the LD Micro Main Event XIX Investor Conference Oct 09, 2025 8:30am EDT Press Release
